Browse

Randomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-naïve Korean patients with extensive-disease small cell lung cancer

DC Field Value Language
dc.contributor.authorKim, Dong-Wan-
dc.contributor.authorKim, Hoon-Gu-
dc.contributor.authorKim, Joo-Hang-
dc.contributor.authorPark, Keunchil-
dc.contributor.authorKim, Hoon-Kyo-
dc.contributor.authorJang, Joung Soon-
dc.contributor.authorKim, Bong-Seog-
dc.contributor.authorKang, Jin-Hyoung-
dc.contributor.authorLee, Kyung Flee-
dc.contributor.authorKim, Sang-We-
dc.contributor.authorRyoo, Hun Mo-
dc.contributor.authorKim, Jin-Soo-
dc.contributor.authorLee, Ki Hyeong-
dc.contributor.authorKwon, Jung Hye-
dc.contributor.authorChoi, Jin-Hyuk-
dc.contributor.authorShin, Sang Won-
dc.contributor.authorHahn, Seokyung-
dc.contributor.authorHeo, Dae Seog-
dc.date.accessioned2020-04-27T10:58:50Z-
dc.date.available2020-04-27T10:58:50Z-
dc.date.issued2019-01-
dc.identifier.citationCancer Research and Treatment, Vol.51 No.1, pp.119-127-
dc.identifier.issn1598-2998-
dc.identifier.other89738-
dc.identifier.urihttps://hdl.handle.net/10371/165214-
dc.description.abstractPurpose This randomized phase III study was designed to compare the efficacy and safety of irinotecan plus cisplatin (IP) over etoposide plus cisplatin (EP) in Korean patients with extensive-disease small-cell lung cancer (SCLC). Materials and Methods Patients were randomly assigned to receive IP, composed of irinotecan 65 mg/m(2) intravenously on days 1 and 8+cisplatin 70 mg/m(2) intravenously on day 1 every 3 weeks, or EP, composed of etoposide 100 mg/m(2) intravenously on days 1, 2, 3+cisplatin 70 mg/m(2) intravenously on day 1, every 3 weeks for a maximum of six cycles, until disease progression, or until unacceptable toxicity occurred. The primary endpoint was overall survival. Results A total of 362 patients were randomized to IP (n=173) and EP (n=189) arms. There were no significant differences between IP and EP arms for the median overall survival (10.9 months vs. 10.3 months, p=0.120) and the median progression-free survival (6.5 months vs. 5.8 months, p=0.115). However, there was a significant difference in response rate (62.4% vs. 48.2%, p=0.006). The pre-planned subgroup analyses showed that IP was associated with longer overall survival in male (11.3 months vs. 10.1 months, p=0.036), <65 years old (12.7 months vs. 11.3 months, p=0.024), and Eastern Cooperative Oncology Group performance status 0/1 (12.4 months vs. 10.9 months, p=0.040) patient groups. The severity of treatment-related adverse events such as grade 3/4 anemia, nausea and diarrhea was more frequent in patients treated with IP. Conclusion The IP chemotherapy did not significantly improve the survival compared with EP chemotherapy in Korean patients with extensive-disease SCLC.-
dc.subjectEtoposide-
dc.subjectIrinotecan-
dc.subjectCisplatin-
dc.subjectSmall cell lung carcinoma-
dc.subjectKorean-
dc.titleRandomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-naïve Korean patients with extensive-disease small cell lung cancer-
dc.typeArticle-
dc.contributor.AlternativeAuthor허대석-
dc.contributor.AlternativeAuthor한서경-
dc.identifier.doi10.4143/crt.2018.019-
dc.citation.journaltitleCancer Research and Treatment-
dc.identifier.scopusid2-s2.0-85051509330-
dc.citation.endpage127-
dc.citation.number1-
dc.citation.startpage119-
dc.citation.volume51-
dc.identifier.rimsid89738-
dc.identifier.sci000455439600013-
dc.identifier.kciidART002430542-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorKim, Dong-Wan-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Cancer Research Institute (암연구소)Journal Papers (저널논문_암연구소)
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse